Latest news for RIWI (OTC:RWCRF) Stock

RIWI Corp is a trend-tracking and prediction technology firm. On a monthly or annual subscription basis, the company offers its clients tracking surveys, continuous risk monitoring, predictive analytics, and ad effectiveness tests in all countries, without collecting any personally identifiable data. Geographically, it derives a majority of revenue from sales in United States. The Company generates revenue from the provision of analytical solutions to its clients in the form of compilation, analysis and communication of real-time data.

News

Penny Stocks

Health Care

Global

Markets

General

RWCRF

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

RIWI: Measuring COVID-19 Resilience Around The World

RIWI Corp

Needham analyst Mike Cikos maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $160 to $200.

Price Target

Analyst Ratings

SNOW

Needham Maintains Buy on Snowflake, Raises Price Target to $200

<ul>
<li>Aphexda is Biolinerx's FDA-Approved Stem Cell Mobilization Agent Indicated In Combination With Filgrastim For Collection And Subsequent Autologous Transplantation In Patients With Multiple Myeloma.</li>
<li>BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23%.</li>
<li>BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC.</li>
<li>BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion.</li>
<li>Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases –</li>
</ul>

Biotech

Contracts

BLRX

BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial Milestones, Plus Royalties Between 18%-23% On Net Sales Of Aphexda

Trimble will provide fleet management and telematics solutions to vehicles across PFG's three business segments including Performance Foodservice Core-Mark and Vistar.&nbsp;
All PFG vehicles will be equipped with Trimble Instinct, Trimble's in-cab ecosystem that seamlessly connects drivers and back-office staff to boost safety, compliance and efficiency.
 &nbsp;

PFGC

TRMB

Performance Food Group Selects Trimble As Its Premier Fleet Management Provider; Migrates 100% Of Its Fleet Management Business To Trimble Instinct, Doubling Trimble-Serviced Trucks To Over 8,000

Earnings

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PDD Holdings Q3 Adj EPADS $2.65 Misses $2.82 Estimate, Sales $14.16B Miss $14.47B Estimate

Artificial intelligence (AI) darling Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/news/earnings/24/11/42099904/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full-steam">beat expectations yet again</a> with impressive third-quarter revenue and earnings reported after Wednesday's market close. 
What happened: The world's most valuable company <a href="https://www.benzinga.com/24/11/42099904/nvidia-q3-earnings-highlights">disclosed </a>third-quarter revenue of $35.1 billion and earnings per share of 81 cents, both beating analysts' estimates.&nbsp;
The Jensen Huang-led firm has had a blockbuster run on equity markets in the last few years, multiplying investors' money by orders of magnitude.&nbsp;
Indeed, Nvidia shares have exploded by 2,718% in the last five years, outperforming all well-known companies on Wall Street.
In comparison, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)—the world's most valued cryptocurrency exerting a similar influence on the digital assets market—grew 1,171% over the last five years.
See Also: <a href="https://www.benzinga.com/24/11/42079799/microstrategys-michael-saylor-to-advocate-for-bitcoin-investment-at-microsoft-board-meeting-offers-to-educate-rumble-ceo-with-the-strategy">Microstrategy&#8217;s Michael Saylor To Advocate For Bitcoin At Microsoft Board Meeting, Offers To Educate Rumble CEO As Well</a>
<h2 class="wp-block-heading">Which Is Offering Better Returns Relative To Risk?</h2>
Both Nvidia and Bitcoin are risk-laden investments, and traders must navigate their inherent volatility to profit.
To get a more accurate picture, analysts track the Sharpe Ratio, a measure of risk-adjusted returns. 
For Bitcoin, this ratio stood at -5 as of this writing, <a href="https://in.tradingview.com/chart/XlzxagWe/?symbol=BITSTAMP%3ABTCUSD">per </a>TradingView, implying that the expected return was lower than that of a risk-free investment, such as a Treasury yield.&nbsp;
On the other hand, Nvidia <a href="https://www.tradingview.com/chart/XlzxagWe/?symbol=NASDAQ%3ANVDA">showed </a>a Sharpe ratio of 0.69, indicating that investment in the stock was generating positive returns above the risk-free rate.
<h2 class="wp-block-heading">Are Their Valuations Inflated?</h2>
Another metric to compare the two hot financial assets was whether they were expensive or cheap relative to their fundamentals.
For stocks, this is typically measured by the price-to-earnings ratio, or simply the P/E ratio.&nbsp;
Nvidia's P/E ratio showed a reading of 73.478 per TradingView, suggesting that the stock was highly overpriced. It could also imply that investors expect the company to have stronger performance and higher earnings in the future.
The P/E counterpart for Bitcoin is the network value to transactions ratio or NVT ratio.
According to on-chain analytics firm <a href="https://cryptoquant.com/asset/btc/chart/network-indicator/nvt-ratio?window=DAY&amp;sma=0&amp;ema=0_30&amp;priceScale=log&amp;metricScale=log&amp;chartStyle=column">CryptoQuant</a>, the 30-day EMA of Bitcoin's NVT was at 28.28 at the time of writing, a decline from 36.32 recorded at the beginning of the month.
The decline implied that transaction volume was outperforming market growth or that valuation had dropped without any change in transaction activity.
Price Action: At the time of writing, Bitcoin was trading at $97,396.60, rising 4.97% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Shares of Nvidia were down 2.49% in after-hours trading.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42079984/dogecoin-bitcoin-left-in-the-dust-by-ai-meme-coin-goat-as-nvidias-q3-earnings-draw-near">Dogecoin, Bitcoin Left In The Dust By AI Meme Coin GOAT As Nvidia&#8217;s Q3 Earnings Draw Near</a></li>
</ul>
Photos courtesy: Nvidia and Pixabay

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Tech

$BTC

NVDA

Nvidia Vs. Bitcoin: Jensen Huang-Led Chip Giant's Stock Outperformed The Top Cryptocurrency Over 5 Years. Here's How They Compare On Other Metrics

Benchmark analyst Cody Acree maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $170 to $190.

Benchmark Maintains Buy on NVIDIA, Raises Price Target to $190

Roth MKM analyst Joe Reagor initiates coverage on Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) with a Buy rating and announces Price Target of $13.

Initiation

SDST

Roth MKM Initiates Coverage On Stardust Power with Buy Rating, Announces Price Target of $13

Morgan Stanley analyst James Faucette upgrades Evertec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTC#NYSE">EVTC</a>) from Underweight to Equal-Weight and raises the price target from $33 to $35.

Upgrades

EVTC

Morgan Stanley Upgrades Evertec to Equal-Weight, Raises Price Target to $35

Morgan Stanley analyst Brian Wilczynski initiates coverage on UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) with a Overweight rating and announces Price Target of $156.

UMBF

Morgan Stanley Initiates Coverage On UMB Financial with Overweight Rating, Announces Price Target of $156

Needham analyst Quinn Bolton maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $145 to $160.

Needham Maintains Buy on NVIDIA, Raises Price Target to $160

Morgan Stanley analyst Judah Frommer initiates coverage on 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Underweight rating and announces Price Target of $8.

FDMT

Morgan Stanley Initiates Coverage On 4D Molecular Therapeutics with Underweight Rating, Announces Price Target of $8

Morgan Stanley analyst Judah Frommer initiates coverage on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight rating and announces Price Target of $31.

APLS

Morgan Stanley Initiates Coverage On Apellis Pharmaceuticals with Equal-Weight Rating, Announces Price Target of $31

Quantum-Si Provides Update On Innovation Roadmap & New Development Partnerships; Announces Next-Generation Platinum System, The Platinum Pro, Scheduled To Launch In H1 Of 2025

Guidance

SCVL

Shoe Carnival Lowers FY24 Net Sales Outlook: Sees Revenues Of $1.20B-$1.23B Vs $1.23B Estimate (Prior View:  $1.23B-$1.25B); Company Reiterates FY24 Adjusted EPS Outlook Of $2.60-$2.75 Vs. $2.63 Estimate

With more than a week of deals planned across the entire assortment, Target will offer some of its lowest prices of the season on thousands of items, including up to 50% off tech, apparel, video games, board games, small appliances, luggage, holiday trees and other must-have items for gifting and gathering.

Target Reveals Its Lineup Of Black Friday Deals Available Now Through Nov. 30 Online And In Its Stores

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) with a Buy and raises the price target from $4 to $5.5.

HC Wainwright & Co. Maintains Buy on Quantum-Si, Raises Price Target to $5.5

This collaboration aims to accelerate the development of advanced ceramic-based microspheres, a groundbreaking advancement in radiotherapeutic applications.
The partnership will see SINTX leverage its expertise in ceramic manufacturing to support NED medical's pre-clinical testing needs and perform the necessary process validation and verification activities to transition the microsphere process from the R&amp;D scale to pilot production.

SINT

SINTX  Signs Joint Development Agreement With NED Medical To Develop Next Generation Radiotherapeutic Solutions That May Have Transformative Impact On Cancer Treatment

Shoe Carnival (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.67 by 5.97 percent. The company reported quarterly sales of $306.885 million which missed the analyst consensus estimate of $316.950 million by 3.18 percent. This is a 4.07 percent decrease over sales of $319.914 million the same period last year.

Earnings Beats

Earnings Misses

Shoe Carnival Q3 2024 Adj. EPS $0.71 Beats $0.67 Estimate, Sales $306.885M Miss $316.950M Estimate

GEHC

GE HealthCare Sets Medium-Term 2026-2028 Targets: Organic Revenue Growth Mid-Single Digit (4% - 6%), Adjusted EPS Growth High-Single Digit To Low-Double Digit

Keefe, Bruyette &amp; Woods analyst Damon Delmonte initiates coverage on Northeast Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBN#NASDAQ">NBN</a>) with a Market Perform rating and announces Price Target of $102.

Keefe, Bruyette & Woods Initiates Coverage On Northeast Bank with Market Perform Rating, Announces Price Target of $102

RIWI GAAP EPS of $0.00, revenue of $1.14M

RIWI GAAP EPS of -$0.01, revenue of $1.03M

RIWI reports Q3 results

Events

Press Releases

RIWI to Present & Participate in 1x1 Meetings at the Planet MicroCap Showcase: VANCOUVER 2024 in association with Small Cap Discoveries on Thursday, September 26, 2024

TSXV:RIWI

RIWI

The following post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga.

Trying to determine the extent that the current pandemic will have on the global economy is difficult. While all the world awaits an effective vaccine, other socio-economic concerns appear in every government agenda. The question remains - how to recover?

There is no magical formula; however, analyzing particular characteristics of regional recovery and institutional experience can help replicate suitable viable solutions. Thus, access to reliable inclusive datasets, indicators, and indexes is critical.

RIWI Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RWCRF#OTC">RWCRF</a>), a global trend-tracking and prediction technology firm selling proprietary data feeds, has been tracking impactful data to help determine decisions that can better define the future. The company currently offers solutions to the global COVID-19 data problem, counting unheard voice, and finding the truth behind the noise.&nbsp;

RIWI understands that data is our greatest ally and that it is essential to know how to interpret the notion of resilience in crisis times to deal with future shocks.&nbsp;

&quot;Companies often rely on legacy polling trackers, which are flawed and do not represent quiet voices that may have a very different opinion of their brand or their product,&quot; said Neil Seeman, Founder, and CEO of RIWI Corp. &quot;In the interests of engaging a diversity of opinion, whether for predicting political outcomes, or better understanding your consumer needs, RIWI offers a differentiated solution in the global data marketplace.&quot;

<h3>Resilience During COVID-19&nbsp;</h3>

<a href="https://www.worldbank.org/en/news/feature/2020/06/08/the-global-economic-outlook-during-the-covid-19-pandemic-a-changed-world" target="_blank">According to the World Bank</a>, we are in the deepest global recession in decades &mdash; the pandemic will leave lasting scars due to job loss, fragmentation of global trade, and supply linkages.

One of the most critical investigations and research of worldwide interest is China&#39;s resilience and what lessons can be learned. The country, where everything started and lockdowns have come to an end, has seen short-term regional strength.

In fact, China adopted early measures, reporting and monitoring the situation, large-scale surveillance, and preparation of medical facilities and supplies, which helped reduce the epidemic. The country was able to cope with the outbreak crisis, and its experts warned of the possible recurrence of the virus stressing the need for caution.

A <a href="https://onlinelibrary.wiley.com/doi/10.1111/tesg.12447" target="_blank">recent study</a> showed that the positive outcome of China would be likely to continue. The results revealed that a complex combination of the current COVID‐19 crisis&rsquo;s characteristics, the institutional experience of dealing with previous pandemic and epidemic crises, government support schemes, and regional industrial structures affects the potential recovery and resilience rates of Chinese regions.

<h3>Emerging Countries</h3>

Unfortunately, not all countries will return to growth levels until <a href="https://www.bloomberg.com/news/articles/2020-10-22/latin-america-won-t-see-pre-virus-growth-until-2023-imf-says" target="_blank">2023</a>, and per capita income is not likely to recover until 2025, according to the International Monetary fund.&nbsp;

Reasons like overcrowded conditions where social distancing is difficult and a high number of informal work that depends on day-to-day earnings make it harder for people to stay home. Thus, creating recovery and prevention measurements is likely impossible.&nbsp;

Emerging markets with daunting vulnerabilities will need detailed data to measure every aspect of the current situation, strengthen public health, manage informality, and encourage sustainable growth once the health crisis is abated. That&rsquo;s why companies like RIWI are essential to show every crucial aspect to determine the next steps to recovery.

&ldquo;When it comes to COVID, we&#39;re only going to solve this problem if we solve the &lsquo;last mile&rsquo; and &lsquo;last inch problem&rsquo;, which is understanding and reducing people&#39;s anxieties associated with vaccination,&rdquo; said Neil Seeman. &ldquo;Many public leaders are increasingly saying, vaccination moves at the speed of trust. RIWI is in the business of measuring trust. And trust is a leading indicator of both economic and public health resilience. And we measure that in all countries of the world.&rdquo;

<h3>Corporate Insights You Should Know</h3>

RIWI is a real-time interactive world-wide intelligence platform that can reach diverse and unbiased audiences in over 220 countries and territories. Top international universities, government agencies, and financial organizations use RIWI technology to monitor risk and evaluate trends by deploying continuous RIWI surveys or digital ad tests.&nbsp;

RIWI produces random, representative opinion data with the broadest possible reach in any country. Its machine-learning technology is based on people stumbling into a RIWI domain that is not commercially active. No personally identifiable information is collected or stored to ensure data quality and client protection. Clients can access RIWI&rsquo;s Web-based dashboard 24/7, and they can download all raw data, unweighted and weighted, into any format.

Photo by <a href="https://unsplash.com/@nasa?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">NASA</a> on <a href="https://unsplash.com/s/photos/globe?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>

The preceding post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Comments

RIWI

News

Latest news for RIWI (OTC:RWCRF) Stock

Monday, December 14, 2020

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga